Partnership to commercialise combination analgesic

摘要

Australian pain drug developer QRxPharma (ASX:QRX) has announced a major partnership for the commercialisation o their lead pain killer compound MoxDuo~(TM) IR in the US acut pain marketplace. The partner is Europe-based Actavis Inc, the fourth largest generic pharmaceutical company in the world.